

Cristina Joao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4300747/publications.pdf>

Version: 2024-02-01

53
papers

1,721
citations

516215

16
h-index

288905

40
g-index

54
all docs

54
docs citations

54
times ranked

2493
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma patients-derived exosomes as a potential new clinical tool. <i>Annals of Medicine</i> , 2024, 51, 46-46.	1.5	0
2	Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?. <i>Hemato</i> , 2022, 3, 63-81.	0.2	1
3	Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?. <i>Hemato</i> , 2022, 3, 385-413.	0.2	2
4	Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness. <i>Pharmacoeconomics</i> , 2021, 39, 579-587.	1.7	10
5	The Immune Microenvironment in Multiple Myeloma: Friend or Foe?. <i>Cancers</i> , 2021, 13, 625.	1.7	21
6	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
7	Boosting Immunity against Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1221.	1.7	8
8	Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET). <i>Blood</i> , 2021, 138, 3939-3939.	0.6	1
9	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.	0.6	6
10	Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1210-1216.	0.5	4
11	Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI. <i>Cancer Imaging</i> , 2020, 20, 6.	1.2	16
12	Liquid biopsies for multiple myeloma in a time of precision medicine. <i>Journal of Molecular Medicine</i> , 2020, 98, 513-525.	1.7	18
13	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	0.6	12
14	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , The, 2019, 20, e302-e312.	5.1	290
15	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
16	Multiple myeloma in elderly patients—a Portuguese multicentric real-life study. <i>Annals of Hematology</i> , 2019, 98, 1689-1701.	0.8	8
17	Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 452-461.	0.9	24
18	PS1364 EXOSOMAL CARGO IN MONOCLONAL GAMMOPATHIES COMPARED TO HEALTHY DONORS AND ITS POTENTIAL RELATION TO MYELOMA AGGRESSIVENESS. <i>HemaSphere</i> , 2019, 3, 623.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies. <i>Journal of Immunology</i> , 2018, 200, 1957-1963.	0.4	26
20	Ibrutinib versus tamsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	3.3	67
21	Predicting Early Mortality in Multiple Myeloma Patients Treated with Novel Agents. <i>Blood</i> , 2018, 132, 5641-5641.	0.6	2
22	Characterization of Circulating and Bone Marrow Derived Exosomes in Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3172-3172.	0.6	2
23	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
24	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus tamsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	0.6	15
25	The Production Processes and Biological Effects of Intravenous Immunoglobulin. <i>Biomolecules</i> , 2016, 6, 15.	1.8	70
26	Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. <i>Annals of Hematology</i> , 2016, 95, 931-936.	0.8	8
27	Ibrutinib versus tamsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2016, 387, 770-778.	6.3	389
28	A national experience of the efficacy and safety of long-term treatment with Lenalidomide in patients with relapsed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e310.	0.2	0
29	Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma—Real life experience of a tertiary cancer center. <i>Annals of Hematology</i> , 2015, 94, 97-105.	0.8	11
30	Central Nervous System infiltration by plasma cells: rare occurrence in Multiple Myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e125-e126.	0.2	0
31	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 469-469.	0.6	3
32	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. <i>Blood</i> , 2015, 126, 4245-4245.	0.6	0
33	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Tamsirolimus. <i>Blood</i> , 2015, 126, 1542-1542.	0.6	0
34	Gamapatias Monoclonais de Significado Indeterminado: Crit�rios de Diagn�stico e Acompanhamento Cl�nico. <i>Acta Medica Portuguesa</i> , 2014, 27, 661.	0.2	0
35	Long-term survival in multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2014, 2, 173-179.	0.2	12
36	Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3481-3481.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Broadened T-cell Repertoire Diversity in ivlg-treated SLE Patients is Also Related to the Individual Status of Regulatory T-cells. <i>Journal of Clinical Immunology</i> , 2013, 33, 349-360.	2.0	22
38	Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model. <i>Journal of Clinical Immunology</i> , 2013, 33, 407-419.	2.0	4
39	Lenalidomide Is Effective Treating Patients With Relapsed Multiple Myeloma and Very Severe Renal Impairment. <i>Blood</i> , 2013, 122, 5401-5401.	0.6	0
40	Advantageous use of lenalidomide in multiple myeloma. <i>Current Opinion in Oncology</i> , 2012, 24, S13-S20.	1.1	2
41	Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivlg-treated SLE patients. <i>Journal of Translational Medicine</i> , 2011, 9, .	1.8	1
42	Treatment With Polyclonal Immunoglobulin During T-cell Reconstitution Promotes Naive T-cell Proliferation. <i>Journal of Immunotherapy</i> , 2010, 33, 618-625.	1.2	11
43	Immunoglobulin is a highly diverse self-molecule that improves cellular diversity and function during immune reconstitution. <i>Medical Hypotheses</i> , 2007, 68, 158-161.	0.8	16
44	Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. <i>Histopathology</i> , 2007, 50, 217-224.	1.6	25
45	The Effect of Infusion of Polyclonal Immunoglobulin or Its Fragments in the Improvement of the Immune Reconstitution after Autologous Stem Cells Transplantation (ASCT) in a Murine Model.. <i>Blood</i> , 2007, 110, 3263-3263.	0.6	13
46	Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2006, 37, 865-871.	1.3	64
47	Immunoglobulin promotes the diversity and the function of T cells. <i>European Journal of Immunology</i> , 2006, 36, 1718-1728.	1.6	16
48	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. <i>Blood</i> , 2005, 106, 1495-1495.	0.6	6
49	Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 5466-5466.	0.6	0
50	B Cell-Dependent TCR Diversification. <i>Journal of Immunology</i> , 2004, 172, 4709-4716.	0.4	75
51	Direct measurement of lymphocyte receptor diversity. <i>Nucleic Acids Research</i> , 2003, 31, 139e-139.	6.5	21
52	Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
53	Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6